Dergiler / Turkish Journal of Gastroenterology / 2021 / Cilt: 32 - Sayı: 9

Efficacy of Lactoferrin with Standard Triple Therapy or Sequential Therapy for Helicobacter pylori Eradication: A Randomized Controlled Trial

Sayfa
742–749
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Conclusion: Bovine lactoferrin could hasten the effectiveness of the proton-pump-based triple therapy or sequential therapy for H. pylori eradication.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Background: Bovine lactoferrin addition to regimens of Helicobacter pylori treatment has been tried, with conflicting results.
📊
Temel Bulgular & Veri:Methods: We enrolled 400 H. pylori-infected patients who were randomized into 4 equal groups: (A): proton-pump-based triple therapy (PpTT) for 2 weeks, (B): sequential therapy for 2 weeks, (C): proton-pump-based triple therapy plus bovine lactoferrin for 2 weeks, and (D): sequential therapy plus bovine lactoferrin for 2 weeks.
💡
Sonuç & Katkı:Conclusion: Bovine lactoferrin could hasten the effectiveness of the proton-pump-based triple therapy or sequential therapy for H. pylori eradication.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Background: Bovine lactoferrin addition to regimens of Helicobacter pylori treatment has been tried, with conflicting results. Aim: To assess the effect of bovine lactoferrin in addition to the anti-H. pylori treatment. Methods: We enrolled 400 H. pylori-infected patients who were randomized into 4 equal groups: (A): proton-pump-based triple therapy (PpTT) for 2 weeks, (B): sequential therapy for 2 weeks, (C): proton-pump-based triple therapy plus bovine lactoferrin for 2 weeks, and (D): sequential therapy plus bovine lactoferrin for 2 weeks. Results: In the per-protocol analysis, the success in groups A, B, C, and D were 70.3%, 82.8%, 85.6%, and 94.5%, respectively (P < .001). The treatment success rate for the sequential therapy plus bovine lactoferrin regimen was significantly higher than that with sequential therapy alone (94.5% vs. 82.8%, P = .013). The same applied for proton-pump-based triple therapy (85.6% vs. 70.3%, P = .014). The addition of bovine lactoferrin and the presence of endoscopic corpus gastritis were independent predictors for successful eradication of H. pylori. Conclusion: Bovine lactoferrin could hasten the effectiveness of the proton-pump-based triple therapy or sequential therapy for H. pylori eradication.

🔖

Bu Makaleye Atıf Yap

HABLASS, F. H., LASHEN, S. A., ALSAYED, E. A. (2021). Efficacy of Lactoferrin with Standard Triple Therapy or Sequential Therapy for Helicobacter pylori Eradication: A Randomized Controlled Trial. Turkish Journal of Gastroenterology, Cilt: 32 - Sayı: 9, 742–749. https://ajindex.com/articles/409183

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (14)

  1. Malfertheiner P, Mégraud F, O’Morain C, European Helicobacter Pylori Study Group (EHPSG), et al. Current concepts in the management of Helicobacter pylori infection — the Maastricht 2-2000 Consensus report. Aliment Pharmacol Ther. 2002
  2. 16(2):167-180. [CrossRef] 2. Moss SF, Malfertheiner P. Helicobacter, and gastric malignancies. Helicobacter. 2007
  3. 12(S1):23-30. [CrossRef] 3. Leodolter A, Kulig M, Brasch H, et al. Meta-analysis comparing eradication, healing, and relapse rates in patients with Helicobacter pylori-associated gastric or duodenal ulcer. Aliment Pharmacol Ther. 2001
  4. 15(12):1949-1958. [CrossRef] 4. Bae SE, Jung HY, Kang J, et al. Effect of Helicobacter pylori eradication on metachronous recurrence after endoscopic resection of gastric neoplasm. Am J Gastroenterol. 2014
  5. 109(1):60-67. [CrossRef] 5. Wang J, Xu L, Shi R, et al. Gastric atrophy and intestinal metaplasia before and after Helicobacter pylori eradication: a meta-analysis. Digestion. 2011
  6. 83(4):253-260. [CrossRef] 6. Nijevitch AA, Idrisov B, Akhmadeeva EN, Graham DY. Choosing optimal first-line Helicobacter pylori therapy: a view from a region with high rates of antibiotic resistance. Curr Pharm Des. 2014
  7. 20(28):4510-4516. [CrossRef] 7. Kim SY, Choi DJ, Chung JW. Antibiotic treatment for Helicobacter pylori: is the end coming? World J Gastrointest Pharmacol Ther. 2015
  8. 6(4):183-198. [CrossRef] 8. Lee SW, Kim HJ, Kim JG. Treatment of helicobacter pylori infection in Korea: a systematic review and meta-analysis. J Korean Med Sci. 2015
  9. 30(8):1001-1009. [CrossRef] 9. Redwan EM, Uversky VN, El-Fakharany EM, Al-Mehdar H. Potential lactoferrin activity against pathogenic viruses. C R Biol. 2014
  10. 337(10):581-595. [CrossRef] 10. Den-Hoed CM, de-Vries AC, Mensink PB, et al. Bovine antibodybased oral immunotherapy for reduction of intragastric Helicobacter pylori colonization: a randomized clinical trial. Can J Gastroenterol. 2011
  11. 25(4):207-213. [CrossRef] 11. Di-Mario F, Aragona G, Dal Bó N, et al. Bovine lactoferrin for Helicobacter pylori eradication: an open, randomized, multicenter study. Aliment Pharmacol Ther. 2006
  12. 23(8):1235-1240. [CrossRef] 12. Wittes J. Sample size calculations for randomized controlled trials. Epidemiol Rev. 2002
  13. 24(1):39-53. [CrossRef] 13. Di-Mario F, Aragona G, Dal Bò N, et al. Use of bovine lactoferrin for Helicobacter pylori eradication. Dig Liver Dis. 2003
  14. 35(10):706- 710. [CrossRef] 14. Yuan Y, Wu Q, Cheng G, et al. Recombinant human lactoferrin enhances the effic